Back to results
US 2025/0017963 A1Published application
Synthetic cytokine circuits to promote infiltration and clearance of immune excluded solid tumors by engineered immune cells
AssigneeThe Regents of the University of California
InventorsWendell A. LIM, Gregory ALLEN
Life of this patent
Estimating the term…
Abstract
Provided herein, among other things, is a cytotoxic immune cell (e.g., a cytotoxic T cell) that expresses an engineered immune receptor (such as a CAR or TCR) whose cytotoxicity within the tumor microenvironment is enhanced by a pro-inflammatory protein that is induced only when the cell binds to either a tissue-specific or cancer-associated antigen. As such, the present cells can be used for the treatment of cancers that are associated with solid tumors.
Claims20
An engineered immune cell comprising the following components:
- (a) a nucleic acid encoding an immune receptor that is activated by binding to a cancer-associated antigen in a solid tumor;
- (b) a binding triggered transcriptional switch (BTTS) that is independently activated by either a tissue- or a cancer-associated antigen in the solid tumor;
- and
- (c) a nucleic acid encoding a pro-inflammatory protein,
- wherein:
- binding of the immune receptor to the cancer-associated antigen activates the immune cell;
- and
- binding of the BTTS to its antigen activates expression of the pro-inflammatory protein and, optionally, the immune receptor if the immune receptor is not constitutively expressed in the cell.
5 more elements
Dependencies are inferred from the claim text.